title: Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma.
abstract: OBJECTIVE
  The objective of this study was to evaluate the prevalence and positron emission tomography (PET) imaging features of pulmonary drug toxicity in patients with lymphoma during or just following chemotherapy.
  
  
  METHODS
  A total of 677 PET scans on 460 patients with lymphoma (351 non-Hodgkin's lymphoma, 92 Hodgkin's disease, and 17 both Hodgkin's and non-Hodgkin's lymphoma) were performed for the evaluation of chemotherapy response. In 51 patients, abnormal accumulation on both sides of the chest was reported. A review of medical records, (18)fluorodeoxyglucose ((18)FDG)-PET scans, and chest computed tomography (CT) was performed, and cases with probable drug toxicity were identified. Inclusion criteria of probable drug toxicity were abnormal but symmetrical FDG accumulation in both lungs seen during or just following the completion of chemotherapy, the abnormal accumulation or corresponding abnormal CT findings resolved on subsequent studies, exclusion of clinical diagnosis of pneumonia, radiation pneumonitis, or lymphoma involvement.
  
  
  RESULTS
  In 10 patients (six men and four women, average age 47.3), 2.2% of cases, probable drug toxicity was identified. In all 10 cases, diffuse and subpleural-dominant FDG accumulation was seen on FDG-PET scans, and scattered or diffuse ground-glass opacities were observed on chest CT. Four patients reported symptoms, and six patients did not report any symptoms.
  
  
  CONCLUSIONS
  Diffuse and peripheral-dominant FDG accumulation in the lung, which may represent pulmonary drug toxicity, was not uncommon in patients with lymphoma who underwent chemotherapy. FDG-PET scan might be able to detect pulmonary drug toxicity in asymptomatic patients.
authors.affiliation: Division of Diagnostic Imaging, the University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. kazamat@fg7.so-net.ne.jp
authors.forename: Toshiki
authors.initials: T
authors.lastname: Kazama
authors.forename: Silvana C
authors.initials: SC
authors.lastname: Faria
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Uchida
authors.forename: Hisao
authors.initials: H
authors.lastname: Ito
authors.forename: Homer A
authors.initials: HA
authors.lastname: Macapinlac
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging* / Q000187:drug effects* / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013909:Thorax / Q000000981:diagnostic imaging / Q000187:drug effects; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18